Raising the bar for treatment expectations in schizophrenia: Achieving remission as a routine goal of antipsychotic pharmacotherapy

Journal of Psychopharmacology

Volumn 20, Issue 6 SUPPL., 2006, Pages 3-5

  Nasrallah, Henry A ^a   Dursun, Serdar M ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE;

CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; FUNCTIONAL ASSESSMENT; GENERAL CONDITION IMPROVEMENT; HAMILTON SCALE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; SYMPTOM;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; PATIENT COMPLIANCE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33750069721     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/1359786806071221     Document Type: Editorial

References (25)

1. Andreasen N, Carpenter W, Kane J, Lasser R, Marder S, Weinberger D (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162: 441-449
2. Ballenger J C, Davidson J R, Lecrubier Y, Nutt D J, Baldwin D S, den Boer J A, Kasper S, Shear M K (1998) Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 59 (Suppl. 8): 47-54
3. Barnes T R E, Curzon D A (1994) Long-acting depot antipsychotics: a risk-benefit assessment. Drug Safety 10: 464-479
4. Burton S (2006) Symptom domains of schizophrenia: the role of atypical antipsychotic agents. J Psychopharmacol 20 (Suppl. 6): 6-19
5. Chue P (2006) The relationship between patient satisfaction and treatment outcomes in schizophrenia. J Psychopharmacol 20 (Suppl. 6): 38-56
6. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David A S (2005) Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15: 111-117
7. David A, Adams C E, Eisenbruch M, Quraishi S, Rathbone J (2005) Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrate Database Syst Rev 2: CD00307
8. Ferrier I N (2001) Characterizing the ideal antidepressant therapy to achieve remission. J Clin Psychiatry 62 (Suppl. 26): 10-15
9. Fleischhacker W W, Eerdekens M, Karcher K, Remington G, Llorca P M, Chrzanowski W, Martin S, Gefvert O (2003) Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64: 1250-1257
10. Frank E, Prien R F, Jarrett R B, Keller M B, Kupfer D J, Lavori P W, Rush A J, Weissman M M (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse and recurrence. Arch Gen Psychiatry 48: 851-855
11. Harding C M, Brooks G W, Ashikaga T, Strauss J S, Breier A (1987) The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry 144: 727-735
12. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube K C, Ganev K, Giel R, an der Heiden W, Holmberg S K, Janca A, Lee P W, Leon C A, Malhotra S, Marsella A J, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin S J, Varma V K, Walsh D, Wiersma D (2001) Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 178: 506-517
13. Kissling W, Kane J, Barnes T, Dencker S, Fleischhacker W, Goldstein M, Johnson D, Marder S, Muller-Spahn F, Tegeler J, Wistedt B, Woggon B (1991) Guidelines for neuroleptic relapse prevention in schizophrenia: towards a consensus view. In Kissling W (ed.), Guidelines for neuroleptic relapse prevention in schizophrenia. Springer-Verlag, Berlin, Heidelberg: 155-163
14. Kordy H, Kramer B, Palmer R L, Papezova H, Pellet J, Richard M, Treasure J (2002) Remission, recovery, relapse, and recurrence in eating disorders: conceptualization and illustration of a validation strategy. J Clin Psychol 55: 833-846
15. Kraepelin E (1919) Dementia Praecox and Paraphrenia. Translated and edited by R B Barclay, E S Livingston, Edinburgh
16. Lasser R A, Bossie C A, Gharabawi G M, Kane J M (2005) Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 77: 215-227
17. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M (1993) Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50: 369-376
18. Lieberman J A, Stroup T S, McEvoy J P, Swartz M S, Rosenheck R A, Perkins D O, Keefe R S, Davis S M, Davis C E, Lebowitz B D, Severe J, Hsiao J K (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223
19. Lindenmayer J P, Eerdekens E, Berry S A, Eerdekens M (2004) Safety and efficacy of long-acting risperidone in schizophrenia: a 12-, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 65: 1084-1089
20. Loebel A D, Lieberman J A, Alvir J M, Mayerhoff D I, Geisler S H, Szymanski S R (1992) Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 149: 1183-1188
21. Nasrallah H, Lasser N (2006) Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol 20 (Suppl. 6): 57-61
22. Ogawa K, Miya M, Watarai A, Nakazawa M, Yuasa S, Utena H (1987) A long-term follow-up study of schizophrenia in Japan - with special reference to the course of social adjustment. Br J Psychiatry 151: 758-765
23. Sheehan D (2001) Defining remission in generalized anxiety disorder: venlfaxine extended release comparative data. J Clin Psychiatry 62: 26-31
24. Turner M, Stewart D (2006) Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J Psychopharmacol 20 (Suppl. 6): 20-37
25. Turner M, Eerdekens E, Jacko M, Eerdekens M (2004) Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 19: 241-249.